Fox Chase Cancer Center News

PHILADELPHIA (February 22, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Joyce G. Habib, MD, as an Assistant Professor in the breast medical oncology program in the Department of Hematology/Oncology.

PHILADELPHIA (February 19, 2024) — Stem cell transplant recipients can reduce their risk of Clostridioides difficile (C. diff) infection by taking the oral antibiotic vancomycin preventively, according to research from Fox Chase Cancer Center presented at a scientific meeting. However, the study also shows that taking this antibiotic can increase these patients’ risk of gram-negative bacteremia.

PHILADELPHIA (February 15, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Lilian Shin-Cho, PhD, as an Assistant Professor in the Cancer Prevention and Control Research Program.

PHILADELPHIA (February 13, 2024) — As part of a recently announced collaboration, Joshua Cohn, MD, FPMRS, an Associate Professor in the Department of Urology at Fox Chase Cancer Center and a member of the Fox Chase – Temple Urologic Institute, will serve as a consultant at Shriners Children’s Philadelphia. He will care for patients with neurogenic urologic conditions, in which a patient lacks bladder control due to injury, neurological disorders, or congenital malformations.

PHILADELPHIA (February 9, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Yash Chhabra, PhD, as an Assistant Professor in the Cancer Signaling and Microenvironment Research Program, where he will focus on the influence of sex disparity in cancer and aging.

PHILADELPHIA (February 2, 2024) — The Lewis Katz School of Medicine at Temple University is pleased to announce the hiring of Amina Abdul-Aziz, PhD, as an Assistant Professor at the Fels Cancer Institute for Personalized Medicine and new member of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center.

PHILADELPHIA (January 26, 2024) — While race can influence treatment recommendations for certain forms of cancer, a new study presented today by researchers at Fox Chase Cancer Center has shown that immune checkpoint inhibitor-based treatment (ICI), a type of immunotherapy, is an equally effective frontline treatment for both Black and white patients with metastatic renal cell carcinoma.

PHILADELPHIA (January 26, 2024) — Patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumor appeared to have an overall survival benefit from subsequent systemic therapy with the immune checkpoint inhibitor nivolumab, according to an analysis by researchers at Fox Chase Cancer Center.